Besides normalisation of haematological parameters, IFN has the potential to induce deep molecular responses in both JAK2-V617F positive MPN patients [17–21] and in a subset of patients with CALR mutated ET patients [22, 23]. The gene discussed is JAK2; the disease is myeloproliferative neoplasm.